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Introduction: Treatment modalities used in locally-advanced cervical cancer include platin-based 
chemotherapy and radiotherapy. However, treatment resistance often develops. Novel treatment 
approaches are therefore needed. Treatment outcome might be improved by sensitizing cervical 
cancer cells for chemo-/radiotherapy using molecularly targeted agents. To effi  ciently screen drug 
candidates, we aimed to investigate the chick embryo chorioallantoic membrane (CAM) assay as 
an in vivo platform to identify chemo-radiotherapy sensitizing compounds using a 3-dimensional 
(3D) in ovo cervical cancer model.
Methods: HeLa cervical cancer cells were inoculated on the CAM of fertilized Dekalb chicken eggs 
at day 6 of embryonic development to establish cervical cancer tumors. Tumors were treated with 
cisplatin and/or ionizing radiation: on day 10 of embryonic development. Hematoxylin and eosin 
staining and immunohistochemical analysis of Ki-67, gamma-H2AX (γ-H2AX) and phosphorylated 
replication protein A 32 (RPA32) were performed to evaluate tumor grafting and therapy delivery. 
Results: Viable 3D cervical cancer tumors were established using the CAM-assay. Tumor reduction 
was observed after a single dose of cisplatin (10 μg: P = 0.03; 50 μg: P = 0.05) or ionizing radiation 
(4, 6 and 8 Gy; all P<0.01) as well as with combined treatment (1 μg cisplatin with either 2 or 4Gy: 
P = 0.02 and P<0.01 respectively).
Conclusion: We have established a 3D-cervical cancer in vivo model by using the CAM assay where 
single or combined treatment with cisplatin or radiation resulted in tumor reduction. Hereby 
we provide a reliable, cost-eff ective and fast screening tool to evaluate chemoradiotherapy-





6. The chick embryo chorioallantoic membrane model as a platform to study chemoradiotherapy responses in cervical cancer
Introduction
Cervical cancer is a common female malignancy which accounts for approximately 8% of all the 
cancer-related deaths of women worldwide [1]. When cervical cancer is locally-advanced, cure is 
primarily achieved by use of platin-based chemoradiotherapy [2-4]. Nonetheless, therapy success 
is not complete; even in stage IIB the 5 year overall survival is 65.8% [5]. 
 In the last decades, multiple molecularly targeted therapies have been developed with the 
aim to potentiate chemotherapeutics or radiotherapy. In the context of cervical cancer, many 
of these compounds have thus far only been tested preclinically [6, 7]. Clinical translation of 
candidate drugs requires careful choices given the large number of drug candidates as well as the 
fact that the pharmacodynamic properties of many of these compounds preclude in vivo testing 
[7]. In preclinical studies novel therapeutic modalities are typically only tested as monotherapy or 
in combination with a single DNA damaging agent [7,8]. Notably, novel compounds are typically 
not tested in the context of chemoradiotherapy, which is the current standard of care in locally 
advanced cervical cancer. An easy and cost-eff ective platform to test novel compounds for their 
chemo- and/or radiosensitizingproperties, is therefore warranted to make a pre-selection for 
further in vivo testing.
 Cell lines xenografted in immune-defi cient mice are frequently used as an intermediate step 
to validate in vitro observations into the in vivo situation. However, testing of series of compounds 
in mice remains expensive, time consuming and goes at the expense of many animals [9]. An 
interesting alternative to effi  ciently select the most promising agents for further testing is the use 
of eggs to perform the chicken embryo chorioallantoic membrane (CAM) assay. 
 The CAM assay is an established model to study angiogenesis, which has been successfully 
employed to investigate novel anti-angiogenetic drug in the context of tumor growth 
and metastasis [10-13]. Many diff erent cell lines, including cervical cancer cell lines, were 
shown to engraft effi  ciently onto the CAM [14-17]. The extensive vascularization and natural 
immunodefi ciency probably contribute to the high grafting rate of the CAM model [18, 19]. 
This model provides important additional advantages compared to in vitro models. Specifi cally, 
engrafted tumors grow 3-dimensionally and are vascularized with bloodvessels originating from 
the CAM [15, 20, 21]. This enables drug delivery via a vascular system and with the CAM model 
being a closed system, the required amounts of the tested agents are limited [22]. Another 
advantage of the CAM assay versus a cell line model is the presence of a microenvironment 
[22, 23]. During tumor inoculation, the ectoderm is mechanically damaged, which results in a 
breached epithelial and basal membrane layer [24, 25]. Tumor cells therefore proliferate while 
being surrounded by epithelial cells and extracellular matrix proteins, originating from the 
mesoderm [23, 26]. Furthermore, the easy handling of the CAM assay and the low cost make it a 
promising preclinical tool for effi  cient selection of drug candidates. 
 Although the characteristics of the chicken embryo CAM model have been previously 
described extensively [12, 14, 15, 27, 28], the combined use of radiotherapy and chemotherapy in 
this model has not been reported thus far. In this study, we have therefore tested the combined 
treatment with cisplatin and ionizing radiation of HeLa cervical cancer cells engrafted on the 
chicken CAM. Our data show that the chicken embryo CAM assay is an effi  cient model to study 
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and selection of novel molecularly targeted compounds in a combined chemoradiotherapy 
setting in a fast, and cost-eff ective way.
 
Results
HeLa cells engraft in ovo and form viable 3D-tumors
To establish a 3-dimensional cervical cancer model for studying anti-cancer therapeutic 
interventions, we fi rst assessed whether HeLa cervical cancer cells can be engrafted on the chicken 
embryo CAM [16, 17]. Our procedure is described in detail in the materials and methods paragraph 
and graphically represented in Figure1A. In summary, 5x10ˆ6 HeLa cells were inoculated onto 
the CAM on day 6, and the chicken embryos were terminated on day 17. Tumor morphology, 
viability as well as proliferation were evaluated by H&E staining and Ki-67 immunostaining 
respectively. As illustrated in Figure 1B, we observed that HeLa tumors consistently showed a 
highly homogenous morphology and were extensively vascularized in ovo. These tumors were 
viable, based on the observed gradual increase in tumor size and the high percentage of Ki-67-
positive cells throughout the entire tumor on day 17. Around 75% of the obtained eggs could 
be used for inoculation, as the remaining part was not fertilized or showed idiopathic embryonic 
mortality between day 0 and 4. Upon inoculation, 100% of chicken embryos survived until day 
17. Notably, we did not observe macroscopic metastases of HeLa cells into the chicken embryo, a 
phenomen on that was observed using other tumor cell lines [11, 29, 30].
Figure 1. HeLa cervical cancer cells in ovo. A. General experimental design of cervical cancer xenografts 
in ovo. B. Immunohistochemical representation for H&E and Ki-67 staining in HeLa xenograft tumors. 
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Cisplatin treatment reduces growth of HeLa xenografts in ovo
Cisplatin is commonly administered as concomitant chemotherapy in advanced cervical cancer 
patients [2]. To examine whether the eff ects of cisplatin treatment can be measured in ovo, we 
fi rst examined whether cisplatin was taken up by the CAM and subsequently delivered to the 
tumor. Cervical cancer xenografts were established on the CAM and left untreated until day 10. 
At this time point, we applied 5 μg cisplatin on the CAM and harvested the tumor 6 hours after 
cisplatin administration. To measure eff ective cisplatin uptake, we assessed the phosphorylation 
of replication protein A-32 (RPA32) on serine-33 (Ser-33), which is an established substrate of 
the ATR kinase, which is activated upon cisplatin treatment (Fig. 2A). Immunohistochemical 
analysis showed increased phosphorylation of RPA32 after treatment with cisplatin, indicating 
that cisplatin systemically arrived in the HeLa xenograft (Fig. 2A). To subsequently assess whether 
cisplatin treatment resulted in tumor weight reduction, we applied diff erent concentrations 
of cisplatin, as previously used in literature (1 μg, 10 μg, 50 μg and 100 μg) [31]. Per condition, 
9-10 fertilized eggs were inoculated, but only 3-4 could be included for analysis per treatment 
group due to lack of engraftment of the tumor cells in eggs, or excess (>25%) CAM tissue in the 
harvested tumors. Signifi cant tumor weight reduction was observed after treatment with a single 
dose of 10 μg cisplatin (P=0.03) and 50 μg cisplatin (P=0.05) (Fig. 2B). Not unexpectedly, cisplatin 
treatment also aff ected viability of the embryo, and we observed a complete embryo mortality at 
17 days after treatment initiation with 100 μg cisplatin [31, 32].
Figure 2. In ovo cisplatin delivery and tumor weight reduction. A. phospho-RPA32 (Ser-33) expression 
in HeLa xenografts in ovo on day 10, at 6 hours after cisplatin (5 μg) administration. B. Tumor weight 
reduction by single-dose treatment of cisplatin (0, 1, 10, 50 and 100 μg) measured on day 17; * P<0.03; 
** P=0.05; § = embryonic lethal dose (100 μg).
Ionizing radiation reduces weight of HeLa xenografts in ovo
Ionizing radiation (IR) is the backbone modality in the treatment of advanced cervical cancer 
[2, 33]. To study whether IR could be effi  ciently delivered in HeLa tumors in ovo, we performed 
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whole egg irradiation (10 Gy) on day 10. At 6 hours after irradiation, tumors were harvested and 
processed for immunohistochemical analysis of DNA breaks, using γH2AX staining. We observed 
increased nuclear γH2AX expression after IR (10 Gy) throughout the tumor (Fig. 3A). Subsequently, 
we tested whether IR treatment reduced tumor weight in ovo. We used increasing doses of IR (0, 
1, 2, 4, 6 and 8 Gy; n=7-15 per condition). Compared to our non-irradiated controls, a signifi cant 
tumor weight reduction (P<0.05) was observed after treatment with 2, 4 and 6 Gy (Fig. 3B). 
Treatment with a dose of 8 Gy resulted in 100% embryonic lethality on day 17, and precluded 
analysis of the xenografted tumor cells (Fig. 3B).
 
Figure 3. In ovo IR delivery and tumor weight reduction by IR. A. γH2AX (Ser-139) expression in HeLa 
in ovo xenografts. Treatment with 5 Gy resulted in increased nuclear γH2AX expression throughout the 
tumor. B. Tumor weight reduction by single-dose IR (0, 1, 2, 4, 6 and 8 Gy) treatment measured on day 
17; * P<0.05; § = embryonic lethal dose (8 Gy).
Combined therapy with cisplatin and ionizing radiation reduces tumor weight in a HeLa in 
ovo xenograft
Finally, we combined irradiation and cisplatin treatment, as this is the standard of care for advanced 
stage cervical cancer patients, and novel therapeutics should ideally be tested in this context. To 
this end, we measured whether a fi xed dose of cisplatin (1 μg), either alone or in combination 
with 2 or 4 Gy IR resulted in reduced tumorweight in ovo (n=15 per condition; Fig. 4A). As a result 
of embryonic death before our endpoint on day 17, diff erences exist in the fi nal numbers of 
included replicates per condition, which are shown in Figure 4A. Importantly, a tumor weight 
reduction was observed with cisplatin combined with either 2 Gy (P= 0.02) or 4 Gy (P<0.01) when 











































Figure 4. In ovo tumor weight reduction by chemoradiotherapy and a model for potential 
experimental set-ups A. Tumor weight reduction by combined chemoradiotherapy (* P=0.02; ** 
P<0.01) in a HeLa CAM xenograft measured on day 17. B. Model that illustrated potential opportunities 
of the CAM model.
Discussion
To our knowledge, this is fi rst report in which combined chemoradiotherapy is examined in 
ovo. We showed that both irradiation and cisplatin eff ectively induce DNA damage in HeLa 
cells in ovo. Treatment-induced DNA damage was assessed by immunohistochemical analysis of 
phospho-RPA32 (phospho-Ser-33) and γH2AX(phospho-Ser-139) for cisplatin and radiotherapy 
respectively. Importantly, both treatments individually as well as in combination resulted in a 
reduction of tumor weight (Fig. 2B, 3B, 4A). We thus propose the CAM HeLa xenograft as a platform 
to study novel therapeutics, such as small molecule DNA repair inhibitors, in combination with 
chemoradiotherapy (Fig. 4B). This model not only allows studying eff ects on tumor growth, but 
also other tumor properties, such as metabolic processes, metastasis and angiogenesis. 
 As in other models, use of chemicals in the CAM assay is restricted by dose-limiting embryonic 
toxicities. Growth of the tumor xenograft will only be maintained when the chicken embryo 





is vital. Single intra-amniotic injection of cisplatin in a range of 0.3-15.0 μg on embryonic day 
5 caused teratogenic or lethal eff ects in chicken embryos [32]. However, administration of 
cisplatinin a later development stage causes less chicken embryo lethality [34]. In literature, 
intravenous injection of 4.7 μg cisplatin on embryonic development day 9, caused 48h after 
cisplatin administration no chicken embryo mortality [34]. We observed no chicken embryo 
lethality with a single dose cisplatin of 1, 10 or 50 μg, when applied on to the CAM. However, it has 
been shown that intravenous injection of 47 μg of cisplatin results in complete mortality 48h after 
administration [34]. This discrepancy between our fi ndings and the reported embryo lethality 
at lower concentrations is likely related to the diff erent route of administration. Specifi cally, our 
route of cisplatin administration directly onto the CAM, likely results in lower cisplatin exposure to 
the embryo, when compared to intravenous injection. Thus, our experiments show that a single 
local administration of 1, 10 or 50 μg cisplatin onto the CAM can be used to study tumor growth 
eff ects, without causing embryo lethality. Analogously, our fi ndings suggest an embryonic 
safe use of ionizing radiation administrated in a single dose of up to 6 Gy, with doses of 8 Gy 
and higher causing embryo lethality. Importantly, not teratogenic eff ects nor additional loss of 
embryo weight was observed when IR (2 Gy or 4 Gy) was used in combination with cisplatin. 
 Specifi c considerations should be made when using xenografted cell lines on the CAM. 
Importantly, chicken embryo movement and hatching will aff ect the ability to accurately 
measure tumor weight on the CAM. The embryo will increasingly occupy the intra-ovo cavity 
during the early stages of embryonic development. Also embryonic movements occur with more 
frequency in later stages of development. Both these factors may infl uence the position of the 
tumor xenograft and infl uence tumor xenograft physiology and consequently may shorten the 
time window when tumor growth can be reliably assessed. In addition, after approximately two 
weeks, the chicken immune system starts to develop, with T and B cells being found around day 
11 and 12 respectively [35]. So although the chicken embryo is considered immune-defi cient, 
chicken embryos eventually become immunocompetent on day 18, which may result in immune 
responses directed against the xenografted tumor cells [36].
 Not withstanding these limitations, the CAM model has numerous advantages. As the CAM 
model is a closed system, only small amounts of candidate drugs are required. Together with the 
low costs of fertilized eggs, and the ability to maintain fertilized eggs in atmospheric incubators, 
results in low overall costs. Additionally, the relatively short duration of the CAM assay allows for 
effi  cient screening of panels of drug candidates and combinations of such drugs with currently 
used radiochemotherapy. Finally, this model has the potential to include the analysis of important 





Chemicals and cell culture
The HeLa cervical cancer cell line was cultured in Dulbecco’s modifi ed Eagle’s medium (DMEM): 
Ham’s F12 (1:1) culture media, supplemented with 10% fetal calf serum and antibiotics (100 U/ml 




line identity (BaseClear, The Netherlands). Upon indicated treatment regimes, HeLa xenografts 
were treated with cisplatin (Tocris Biosciences) and/or exposed to a cesium137 source (0.01083 
Gy/s; CIS International/IBL 637). 
CAM-assay procedure
Previously described protocols were adapted and optimized for our lab [13, 16, 18, 20, 22]. In 
summary, fertilized Dekalb chicken eggs (from 26-50 weeks old chickens) were rinsed with 
70% ethanol and incubated while rotating in a 37°C and 60% humidifi ed atmosphere on day 
1. On day 3, rotation was discontinued and an airpocket was created via puncture of the shell 
with a 26 gauge needle, to allow the CAM to dissociate from the shell. The punctured hole was 
covered with tape, and eggs were returned to the incubator. On day 6, embryo viability was 
confi rmed based on visual inspection of blood vessels establishment using a lamp. If vital, the 
opening in the shell was widened to create a greater window. Subsequently, the CAM was 
gently mechanically damaged to stimulate re-vascularization, and the CAM was then inoculated 
with 5x10ˆ6 HeLa cells in 50 μl of ice-cold culture media mixed 1:1 with Matrigel (Corning, 
#356230). The window was again covered with tape and returned to the incubator. Conform 
literature, treatment intervention has started at 96 hours after inoculation (at day 10), when tumor 
cells were engrafted and vascularized (see Figure1A for timeline) [21]. Treatment consisted of 
cisplatin and radiotherapy. If indicated, 3 hours prior to cisplatin treatment, an elastic latex ring 
(Dentsply International) was applied onto the CAM to ensure administration of cisplatin locally 
at a distant site from the tumor, and to ensure that cisplatin uptake in the tumor was through 
blood vessels. Ifi ndicated, whole egg irradiation was used with indicated doses (CIS International/ 
IBL 637, equipped with a cesium-137 source, 0.01083 Gy/s). Chicken embryos were terminated on 
day 17 and tumors were excised from the CAM. Tumors were weighted prior to fi xation in 4% 
formaldehyde and were subsequently paraffi  n-embedded. 
 
Immunohistochemistry
Tumors were sectioned into 4 μm slices and mounted on amino-propyl-ethoxy-silan-coated glass 
slides. Before staining, xylene was used to deparaffi  nize tissue slides. Blocking of endogenous 
peroxidase was performed by incubation for 30 minutes with 0.3% hydrogen peroxidase. Slides 
were stained with hematoxylin and eosin (H&E) for histopathological analysis. On serial slides, DAB 
staining was used to visualize antibody staining and hematoxylin was used for counterstaining. 
Slides were either stained for phosphorylated replication protein A 32 (pRPA32) on serine-33 
(ser-33), gamma-H2AX (γ-H2AX) on serine 139 (ser-139) or Ki-67. Further details of antigen 
retrieval, primary antibodies and detection methods are summarized in Supplemental Table 1. 
Representative control immunostainings of used antibodies are demonstrated in Supplemental 
Figures 1 and 2. 
 
Statistical analysis
Data were expressed as the means ± standard deviations (SD). The diff erences between two 
groups were analyzed using the one-way Mann-Whitney U-test. Eggs were included for statistical 
analysis when 1) tumor cells showed successful engraftment as judged by proliferation, tumor 





architecture and tumor integrity), and 2) >75% of the tissue with the H&E staining consisted of 
tumor cells. Therapy eff ects were measured by tumor weight. Statistical analyses were performed 
using GraphPad Prism version 6.00 for Windows (GraphPad software). Statistical diff erences were 
considered signifi cant if P<0.05.
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H2AX  Millipore 05-636  Citrate (pH 6.0) 1:300 60 minutes RT RAMpo- GARpo 
pRPA32  Bethyl A300-246A TRIS/HCL (pH 9.0) 1:1500 60 minutes RT Avidin- biotin 
Ki-67 Abcam Ab15580 Citrate (pH 6.0) 1:500 60 minutes RT GARpo- RAGpo 
 
TRIS = tris(hydroxymethyl)aminomethane; HCL = hydrochloric acid; No. = number; RT = room temperature; RAMpo = 
Rabbit Anti-Mouse horseradish peroxidase; GARpo = Goat Anti-Rabbit horseradish peroxidase; RAGpo = Rabbit Anti-
Goat horseradish peroxidase; o/n = overnight. 
 
Supplementals
Supplemental Table1. Details of antibodies used for immunohistochemical analysis.
Supplemental Figure 1. A, H&E staining in HeLa xenograft tumor as used for Ki-67 staining in Figure 1 






















































Supplemental Figure 2. A, representative immunostainings for IgG antibodies for phospho-RPA32 
and γH2AX in para n embedded HeLa cell line pellets. Cells were 6 hours before harvesting treated with 
5μM cisplatin. B, representative immunostainings for phospho-RPA32 (S33) and γH2AX (S139) in para 
n embedded HeLa cell line pellets which were either untreated or treated with cisplatin 6 hours before 
harvesting. C, representative immunostainings for phospho-RPA32 (S33) and γH2AX (S139) in in ovo 
HeLa xenograft. Six hours after cisplatin or vehicle treatment, HeLa xenografts were harvested.
